{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:56:02Z","timestamp":1790758562844,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"DOI":"10.1007\/s40122-026-00895-y","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:02:15Z","timestamp":1790755335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Persistence and Reasons for Treatment Discontinuation of Anti-CGRP Therapies in Migraine Prophylaxis: A Systematic Review and Meta-analysis of Real-World Studies"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-5039","authenticated-orcid":false,"given":"Lanfranco","family":"Pellesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidin","family":"Yangjeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Hajjaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9505-6135","authenticated-orcid":false,"given":"Dilara","family":"Onan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-2803","authenticated-orcid":false,"given":"Marta","family":"Waliszewska-Pros\u00f3\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-4128","authenticated-orcid":false,"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"1","key":"895_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01889-x","volume":"25","author":"A Raggi","year":"2024","unstructured":"Raggi A, Leonardi M, Arruda M, et al. Hallmarks of primary headache: part 1\u2014migraine. J Headache Pain. 2024;25(1):189.","journal-title":"J Headache Pain"},{"issue":"1","key":"895_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02192-z","volume":"26","author":"AK Hus\u00f8y","year":"2023","unstructured":"Hus\u00f8y AK, Steiner TJ. GBD 2023: over twice the health loss from headache disorders among females compared with males, and one fifth of the loss is attributable to medication overuse. J Headache Pain. 2023;26(1):227.","journal-title":"J Headache Pain"},{"issue":"6","key":"895_CR3","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478\u201388.","journal-title":"Cephalalgia"},{"issue":"1","key":"895_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01753-y","volume":"25","author":"R Oliveira","year":"2024","unstructured":"Oliveira R, Gil-Gouveia R, Puledda F. CGRP-targeted medication in chronic migraine - systematic review. J Headache Pain. 2024;25(1):51.","journal-title":"J Headache Pain"},{"key":"895_CR5","doi-asserted-by":"publisher","unstructured":"Khalili M, Haghdoost F, Liaghatdar A, et al. Effectiveness and tolerability of pharmacological prophylaxis for\u00a0migraine\u00a0headaches: a systematic review and\u00a0network\u00a0meta-analysis of randomised controlled trials. BMJ Evid Based Med. 2026:bmjebm-2025-114222. https:\/\/doi.org\/10.1136\/bmjebm-2025-114222","DOI":"10.1136\/bmjebm-2025-114222"},{"key":"895_CR6","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71.","journal-title":"BMJ"},{"issue":"12","key":"895_CR7","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s40263-025-01235-y","volume":"39","author":"LF Iannone","year":"2025","unstructured":"Iannone LF, Boccalini A, Lo Castro F, et al. Effect of atogepant on sleep quality and sleep-related adverse events in adult patients with migraine: a prospective observational 12-week study. CNS Drugs. 2025;39(12):1341\u201354.","journal-title":"CNS Drugs"},{"issue":"1","key":"895_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02239-1","volume":"27","author":"A Mu\u00f1oz-Vendrell","year":"2025","unstructured":"Mu\u00f1oz-Vendrell A, Campoy-D\u00edaz S, Val\u00edn-Villanueva P, et al. Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response. J Headache Pain. 2025;27(1):2.","journal-title":"J Headache Pain"},{"issue":"1","key":"895_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02180-3","volume":"26","author":"AP Andreou","year":"2025","unstructured":"Andreou AP, Hill B, Al-Rawi R, et al. A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience. J Headache Pain. 2025;26(1):235.","journal-title":"J Headache Pain"},{"issue":"1","key":"895_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02138-5","volume":"26","author":"M Romozzi","year":"2025","unstructured":"Romozzi M, Lokhandwala A, Vollono C, et al. A nomogram for the prediction of response to anti-CGRP mAbs: the CGRP score. J Headache Pain. 2025;26(1):190.","journal-title":"J Headache Pain"},{"issue":"8","key":"895_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251370608","volume":"45","author":"A Russo","year":"2025","unstructured":"Russo A, Silvestro M, Finkelstein I, et al. Effectiveness and tolerability of atogepant as preventive treatment in resistant individuals with chronic migraine: six-month real-world evidence. Cephalalgia. 2025;45(8):3331024251370608.","journal-title":"Cephalalgia"},{"issue":"1","key":"895_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s42466-025-00395-y","volume":"7","author":"S Suzuki","year":"2025","unstructured":"Suzuki S, Suzuki K, Haruyama Y, et al. A real-world study of the efficacy and tolerability of fremanezumab in migraine patients with a median follow-up of 14 months. Neurol Res Pract. 2025;7(1):37.","journal-title":"Neurol Res Pract"},{"issue":"6","key":"895_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251346925","volume":"45","author":"A Jaimes","year":"2025","unstructured":"Jaimes A, Rodr\u00edguez-Vico J, Pajares O, et al. Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: the RESCUE study. Cephalalgia. 2025;45(6):3331024251346925.","journal-title":"Cephalalgia"},{"issue":"6","key":"895_CR14","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/head.14913","volume":"65","author":"A L\u00f3pez-Bravo","year":"2025","unstructured":"L\u00f3pez-Bravo A, M\u00ednguez-Olaondo A, Nieves-Castellanos C, et al. Patient satisfaction with calcitonin gene-related peptide monoclonal antibodies in migraine: a multicenter prospective cohort study. Headache. 2025;65(6):994\u20131004.","journal-title":"Headache"},{"issue":"3","key":"895_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030734","volume":"14","author":"MK Kang","year":"2025","unstructured":"Kang MK, Sohn JH, Cha MJ, et al. One-year compliance after calcitonin gene-related peptide monoclonal antibody therapy for migraine patients in a real-world setting: a multicenter cross-sectional study. J Clin Med. 2025;14(3):734.","journal-title":"J Clin Med"},{"issue":"1","key":"895_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/head.14788","volume":"65","author":"R Ornello","year":"2025","unstructured":"Ornello R, Baldini F, Onofri A, et al. Impact of duration of chronic migraine on long-term effectiveness of monoclonal antibodies targeting the calcitonin gene-related peptide pathway\u2014a real-world study. Headache. 2025;65(1):61\u20137.","journal-title":"Headache"},{"key":"895_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/ane\/6650009","author":"A Mu\u00f1oz-Vendrell","year":"2025","unstructured":"Mu\u00f1oz-Vendrell A, Campoy S, Cano S\u00e1nchez LM, et al. Monthly versus quarterly fremanezumab in real life: a comparison of effectiveness, tolerability, and adherence. Acta Neurol Scand. 2025. https:\/\/doi.org\/10.1155\/ane\/6650009.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"895_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/head.14827","volume":"65","author":"A de Dios","year":"2025","unstructured":"de Dios A, Pag\u00e8s-Puigdemont N, Ojeda S, et al. Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine. Headache. 2025;65(1):24\u201334.","journal-title":"Headache"},{"issue":"12","key":"895_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16450","volume":"31","author":"LF Iannone","year":"2024","unstructured":"Iannone LF, Romozzi M, Russo A, et al. Association of anti-calcitonin gene-related peptide with other monoclonal antibodies for different diseases: a multicenter, prospective, cohort study. Eur J Neurol. 2024;31(12):e16450.","journal-title":"Eur J Neurol"},{"issue":"12","key":"895_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16410","volume":"31","author":"L Zanandrea","year":"2024","unstructured":"Zanandrea L, Messina R, Cetta I, et al. Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: an Italian, multicenter, real-life study. Eur J Neurol. 2024;31(12):e16410.","journal-title":"Eur J Neurol"},{"issue":"22","key":"895_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e40190","volume":"10","author":"T Tanei","year":"2024","unstructured":"Tanei T, Fuse Y, Maesawa S, et al. Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization. Heliyon. 2024;10(22):e40190.","journal-title":"Heliyon"},{"issue":"11","key":"895_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/pm\/pnae050","volume":"25","author":"S Kikui","year":"2024","unstructured":"Kikui S, Daisuke D, Miyahara J. Effectiveness of fremanezumab treatment in patients with migraine headache. Pain Med. 2024;25(11):664\u201370.","journal-title":"Pain Med"},{"issue":"10","key":"895_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241288875","volume":"44","author":"P Triller","year":"2024","unstructured":"Triller P, Blessing VN, Overeem LH, et al. Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: a retrospective cohort study. Cephalalgia. 2024;44(10):3331024241288875.","journal-title":"Cephalalgia"},{"issue":"9","key":"895_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16372","volume":"31","author":"YF Wang","year":"2024","unstructured":"Wang YF, Yang FC, Chen LA, et al. Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: a multicenter, real-world study in Taiwan. Eur J Neurol. 2024;31(9):e16372.","journal-title":"Eur J Neurol"},{"issue":"8","key":"895_CR25","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1080\/01616412.2024.2354618","volume":"46","author":"JY Al-Hashel","year":"2024","unstructured":"Al-Hashel JY, Alroughani R, Alshaf F, et al. Real-world experiences of migraine patients on Erenumab: a Kuwait single-center cohort. Neurol Res. 2024;46(8):772\u201380.","journal-title":"Neurol Res"},{"issue":"7","key":"895_CR26","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1007\/s10072-024-07380-4","volume":"45","author":"C Rosignoli","year":"2024","unstructured":"Rosignoli C, Caponnetto V, Onofri A, et al. Monoclonal antibodies targeting the calcitonin gene-related peptide pathway improve the effectiveness of acute medication-a real-world study. Neurol Sci. 2024;45(7):3305\u201312.","journal-title":"Neurol Sci"},{"issue":"7","key":"895_CR27","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/head.14737","volume":"64","author":"YJ Zhao","year":"2024","unstructured":"Zhao YJ, Ong JJY, Sonu SK, et al. A real-world prospective observational study of eptinezumab in Asian patients with migraine. Headache. 2024;64(7):810\u201324.","journal-title":"Headache"},{"issue":"2","key":"895_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40120-024-00582-0","volume":"13","author":"F Vernieri","year":"2024","unstructured":"Vernieri F, Iannone LF, Guerzoni S, et al. Long-term effectiveness of galcanezumab in the prevention of migraine: an Italian retrospective analysis (REALITY). Neurol Ther. 2024;13(2):415\u201335.","journal-title":"Neurol Ther"},{"issue":"3","key":"895_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12030677","volume":"12","author":"A Della Vecchia","year":"2024","unstructured":"Della Vecchia A, De Luca C, Becattini L, et al. Beyond pain relief: unveiling the multifaceted impact of anti-CGRP\/R mAbs on comorbid symptoms in resistant migraine patients. Biomedicines. 2024;12(3):677.","journal-title":"Biomedicines"},{"key":"895_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1370503","volume":"15","author":"T Koelsche","year":"2024","unstructured":"Koelsche T, Nikolov P, Koska V, et al. Additional effect of erenumab for patients with chronic migraine treated with onabotulinumtoxin A-real-world data from a preliminary cohort study. Front Neurol. 2024;15:1370503.","journal-title":"Front Neurol"},{"issue":"1","key":"895_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000547","volume":"6","author":"JC Ray","year":"2024","unstructured":"Ray JC, Dalic L, Baker J, Cheng S, Hutton EJ, Matharu M. Twelve-month efficacy of CGRP monoclonal antibodies and predictive value of short-term response: results of an Australian multicentre study. BMJ Neurol Open. 2024;6(1):e000547.","journal-title":"BMJ Neurol Open"},{"issue":"12","key":"895_CR32","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s40263-023-01050-3","volume":"37","author":"V Caponnetto","year":"2023","unstructured":"Caponnetto V, Russo A, Silvestro M, et al. Long-term treatment over 52 weeks with monthly fremanezumab in drug-resistant migraine: a prospective multicenter cohort study. CNS Drugs. 2023;37(12):1069\u201380.","journal-title":"CNS Drugs"},{"issue":"6","key":"895_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2799","volume":"13","author":"S Guerzoni","year":"2023","unstructured":"Guerzoni S, Baraldi C, Castro FL, Cainazzo MM, Pani L. Galcanezumab for the treatment of chronic migraine and medication overuse headache: real-world clinical evidence in a severely impaired patient population. Brain Behav. 2023;13(6):e2799.","journal-title":"Brain Behav"},{"issue":"2","key":"895_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16106","volume":"31","author":"S de Vries Lentsch","year":"2024","unstructured":"de Vries Lentsch S, van der Arend BWH, de Boer I, van Zwet EW, MaassenVanDenBrink A, Terwindt GM. Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine. Eur J Neurol. 2024;31(2):e16106.","journal-title":"Eur J Neurol"},{"issue":"1","key":"895_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01690-2","volume":"24","author":"V Obach","year":"2023","unstructured":"Obach V, Velasco F, Alvarez Escudero R, et al. Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real-world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry. J Headache Pain. 2023;24(1):157.","journal-title":"J Headache Pain"},{"issue":"1","key":"895_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01680-4","volume":"24","author":"M Lanteri-Minet","year":"2023","unstructured":"Lanteri-Minet M, Fabre R, Martin C, et al. One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study. J Headache Pain. 2023;24(1):152.","journal-title":"J Headache Pain"},{"issue":"5","key":"895_CR37","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s13311-023-01394-0","volume":"20","author":"G Lambru","year":"2023","unstructured":"Lambru G, Caponnetto V, Hill B, et al. Long-term effect of switching from an anti-CGRP receptor to an anti-CGRP ligand antibody in treatment-refractory chronic migraine: a prospective real-world analysis. Neurotherapeutics. 2023;20(5):1284\u201393.","journal-title":"Neurotherapeutics"},{"issue":"17","key":"895_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175619","volume":"12","author":"H Haneke","year":"2023","unstructured":"Haneke H, Sulaiman S, Nickel S, Raffaelli B, Jansen JP, Kirchberger V. Changes in health-related quality of life in patients with therapy-resistant migraine during treatment with erenumab in an ambulatory care setting. J Clin Med. 2023;12(17):5619.","journal-title":"J Clin Med"},{"issue":"7","key":"895_CR39","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1111\/ene.15816","volume":"30","author":"M Torres-Ferrus","year":"2023","unstructured":"Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Gin\u00e9-Cipr\u00e9s E, Pozo-Rosich P. Patterns of response to anti-calcitonin gene-related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: impact on outcome. Eur J Neurol. 2023;30(7):1937\u201344.","journal-title":"Eur J Neurol"},{"issue":"5","key":"895_CR40","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1111\/ene.15740","volume":"30","author":"AA Argyriou","year":"2023","unstructured":"Argyriou AA, Dermitzakis EV, Xiromerisiou G, et al. Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: prospective, multicenter, real-world data from a Greek registry. Eur J Neurol. 2023;30(5):1435\u201342.","journal-title":"Eur J Neurol"},{"issue":"2","key":"895_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40263-022-00983-5","volume":"37","author":"LF Iannone","year":"2023","unstructured":"Iannone LF, Fattori D, Marangoni M, et al. Switching onabotulinumtoxinA to monoclonal anti-CGRP antibodies in drug-resistant chronic migraine. CNS Drugs. 2023;37(2):189\u2013202.","journal-title":"CNS Drugs"},{"issue":"6","key":"895_CR42","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/head.14528","volume":"63","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Braca S, Sansone M, et al. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine. Headache. 2023;63(6):788\u201394.","journal-title":"Headache"},{"key":"895_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1226591","volume":"14","author":"CK Cullum","year":"2023","unstructured":"Cullum CK, Chaudhry BA, Do TP, Amin FM. Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study. Front Neurol. 2023;14:1226591.","journal-title":"Front Neurol"},{"issue":"1","key":"895_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01536-3","volume":"24","author":"E Troy","year":"2023","unstructured":"Troy E, Shrukalla AA, Buture A, et al. Medium-term real-world data for erenumab in 177 treatment-resistant or difficult-to-treat chronic migraine patients: persistence and patient-reported outcome measures after 17\u201330\u2009months. J Headache Pain. 2023;24(1):5.","journal-title":"J Headache Pain"},{"issue":"1","key":"895_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01507-8","volume":"23","author":"AP Andreou","year":"2022","unstructured":"Andreou AP, Fuccaro M, Hill B, et al. Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis. J Headache Pain. 2022;23(1):139.","journal-title":"J Headache Pain"},{"issue":"1","key":"895_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01480-2","volume":"23","author":"R De Icco","year":"2022","unstructured":"De Icco R, Vaghi G, Allena M, et al. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial. J Headache Pain. 2022;23(1):123.","journal-title":"J Headache Pain"},{"issue":"4","key":"895_CR47","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s13760-021-01770-7","volume":"122","author":"P Storch","year":"2022","unstructured":"Storch P, Burow P, M\u00f6ller B, et al. Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice. Acta Neurol Belg. 2022;122(4):931\u20137.","journal-title":"Acta Neurol Belg"},{"issue":"6","key":"895_CR48","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1080\/00325481.2022.2080381","volume":"134","author":"A Krymchantowski","year":"2022","unstructured":"Krymchantowski A, Silva-N\u00e9to RP, Jevoux C, Krymchantowski AG. Brazilian descriptive study of 104 consecutive real-world migraine patients treated with monoclonal antibodies. Postgrad Med. 2022;134(6):598\u2013602.","journal-title":"Postgrad Med"},{"issue":"6","key":"895_CR49","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/ane.13599","volume":"145","author":"A L\u00f3pez-Bravo","year":"2022","unstructured":"L\u00f3pez-Bravo A, Oliveros-Cid A, Sevillano-Orte L. Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: a real-life experience in migraine. Acta Neurol Scand. 2022;145(6):669\u201375.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"895_CR50","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/ene.15197","volume":"29","author":"F Vernieri","year":"2022","unstructured":"Vernieri F, Altamura C, Brunelli N, et al. Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol. 2022;29(4):1198\u2013208.","journal-title":"Eur J Neurol"},{"key":"895_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2022.107169","volume":"214","author":"D Mahovi\u0107","year":"2022","unstructured":"Mahovi\u0107 D, Bra\u010di\u0107 M, Jaku\u0161 L, Vukovic Cvetkovic V, Krpan M. Effectiveness and safety of erenumab in chronic migraine: a Croatian real-world experience. Clin Neurol Neurosurg. 2022;214:107169.","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"895_CR52","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s10072-021-05426-5","volume":"43","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V, et al. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci. 2022;43(2):1273\u201380.","journal-title":"Neurol Sci"},{"issue":"12","key":"895_CR53","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1111\/ene.15075","volume":"28","author":"S de Vries Lentsch","year":"2021","unstructured":"de Vries Lentsch S, Verhagen IE, van den Hoek TC, MaassenVanDenBrink A, Terwindt GM. Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: a real-life study. Eur J Neurol. 2021;28(12):4194\u2013203.","journal-title":"Eur J Neurol"},{"issue":"1","key":"895_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01333-4","volume":"22","author":"S Bottiroli","year":"2021","unstructured":"Bottiroli S, De Icco R, Vaghi G, et al. Psychological predictors of negative treatment outcome with erenumab in chronic migraine: data from an open-label long-term prospective study. J Headache Pain. 2021;22(1):114.","journal-title":"J Headache Pain"},{"issue":"10","key":"895_CR55","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1007\/s10072-021-05105-5","volume":"42","author":"MM Cainazzo","year":"2021","unstructured":"Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, Guerzoni S. Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. Neurol Sci. 2021;42(10):4193\u2013202.","journal-title":"Neurol Sci"},{"key":"895_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.687697","volume":"12","author":"A Tziakouri","year":"2021","unstructured":"Tziakouri A, Tsangari H, Michaelides C. Assessment of the effect of erenumab on efficacy and quality-of-life parameters in a cohort of migraine patients with treatment failure in Cyprus. Front Neurol. 2021;12:687697.","journal-title":"Front Neurol"},{"issue":"10","key":"895_CR57","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/head.13968","volume":"60","author":"S Cheng","year":"2020","unstructured":"Cheng S, Jenkins B, Limberg N, Hutton E. Erenumab in chronic migraine: an Australian experience. Headache. 2020;60(10):2555\u201362.","journal-title":"Headache"},{"issue":"1","key":"895_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):32.","journal-title":"J Headache Pain"},{"issue":"9","key":"895_CR59","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Cevoli S, et al. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache. 2021;61(9):1351\u201363. https:\/\/doi.org\/10.1111\/head.14194.","journal-title":"Headache"},{"issue":"4","key":"895_CR60","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644\u201355.","journal-title":"Headache"},{"issue":"1","key":"895_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01472-2","volume":"23","author":"X Wang","year":"2022","unstructured":"Wang X, Wen D, He Q, You C, Ma L. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. J Headache Pain. 2022;23(1):105.","journal-title":"J Headache Pain"},{"issue":"1","key":"895_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02256-0","volume":"27","author":"CL Hoehne","year":"2026","unstructured":"Hoehne CL, Overeem LH, Sanchez-Del-Rio M, et al. Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review. J Headache Pain. 2026;27(1):10.","journal-title":"J Headache Pain"},{"issue":"1","key":"895_CR63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s10194-025-02167-0","volume":"27","author":"CS Moura","year":"2025","unstructured":"Moura CS, Randall JR, Klarenbach S, et al. Persistence, switching, and healthcare use after initiating calcitonin gene-related peptide inhibitors: a real-world assessment. J Headache Pain. 2025;27(1):19.","journal-title":"J Headache Pain"},{"issue":"1","key":"895_CR64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s10194-023-01539-8","volume":"24","author":"L Al-Hassany","year":"2023","unstructured":"Al-Hassany L, Lyons HS, Boucherie DM, et al. The sense of stopping migraine prophylaxis. J Headache Pain. 2023;24(1):9.","journal-title":"J Headache Pain"},{"issue":"1","key":"895_CR65","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s10194-025-02028-w","volume":"26","author":"L Pellesi","year":"2025","unstructured":"Pellesi L, Do TP, Ernst MT, Hallas J, Potteg\u00e5rd A. Adoption of rimegepant in Denmark: a register-based study on uptake, prescribing patterns and initiator characteristics. J Headache Pain. 2025;26(1):83.","journal-title":"J Headache Pain"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-026-00895-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-026-00895-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-026-00895-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:02:16Z","timestamp":1790755336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-026-00895-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":65,"alternative-id":["895"],"URL":"https:\/\/doi.org\/10.1007\/s40122-026-00895-y","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"4 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lanfranco Pellesi has received consulting fees from Eli Lilly. Paolo Martelletti is an Editorial Board member of Pain and Therapy. Paolo Martelletti was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Aidin Yangjeh, Ibrahim Hajjaj, Dilara Onan, and Marta Waliszewska-Pros\u00f3\u0142 have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}